CTOs on the Move

Hospria

www.hospria.com

 
Hospria is a Lake Forest, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 5K-10K
  • Annual Revenue: > $1 Billion
  • www.hospria.com
  • 275 N Field Dr
    Lake Forest, IL USA 60045
  • Phone: 224.212.2000

Executives

Name Title Contact Details

Similar Companies

Insitus Biotechnologies

Insitus Biotechnologies is a Albuquerque, NM-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Purdue Pharma

Purdue Pharma L.P. is a privately held pharmaceutical company founded by physicians more than 60 years ago. We are committed to advancing the care of patients with innovative, quality products that make a positive impact on healthcare — and on lives. Purdue Pharma is part of a global network of independent associated companies that is known for pioneering research in chronic pain and opioids with abuse deterrent properties. The Company is engaged in the research, development, production, and marketing of prescription medicines and over-the-counter healthcare products. We are pursuing a promising pipeline of new medications through internal research & development and strategic industry partnerships. At Purdue, we embrace our mission to find, develop, and introduce innovative medicines that meet the evolving needs of healthcare professionals, patients and caregivers.

Volastra Therapeutics

Volastra aims to extend the lives of patients with cancer by leveraging unique insights into chromosomal instability. Moving away from primary tumor models to target the site of metastasis in the toughest-to-treat solid tumors, we are altering the treatment paradigm for metastatic cancers.

Somaxon Pharmaceuticals, Inc.

Somaxon Pharmaceuticals, Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Raptor Pharmaceuticals

Raptor is a NASDAQ-listed biopharmaceutical company with the mission to develop and commercialize life-altering therapeutics that treat debilitating and often fatal diseases. Raptor`s lead product, PROCYSBI (cysteamine bitartrate) delayed-release capsules, received FDA approval on April 30, 2013. The Company anticipates receiving a determination from the EMA regarding its PROCYSBI marketing application in the European Union in the second half of 2013. Raptor’s product pipeline may advance therapeutic options for additional indications. Raptor`s management team consists of repeat entrepreneurs with the experience to build a successful company.